This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
KalVista Pharmaceuticals, Inc. (KALV) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
KalVista Pharmaceuticals, Inc. (KALV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Options Traders Betting on a Big Move in KalVista Pharmaceuticals (KALV) Stock?
by Zacks Equity Research
Investors need to pay close attention to KalVista Pharmaceuticals (KALV) stock based on the movements in the options market lately.
KalVista Pharmaceuticals (KALV) Catches Eye: Stock Jumps 7.4%
by Zacks Equity Research
KalVista Pharmaceuticals (KALV) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Corcept (CORT) Q4 Earnings In-Line with Estimates, Up Y/Y
by Zacks Equity Research
Corcept Therapeutics (CORT) reports in-line earnings in the fourth quarter of 2020.
Pacira's (PCRX) Q4 Earnings Top Estimates, Revenues In Line
by Zacks Equity Research
Pacira (PCRX) beats earnings estimates in the fourth quarter of 2019. Revenues are in line with estimates.
The Zacks Analyst Blog Highlights: ResMed, Ensign, DaVita, KalVista Pharmaceuticals and MEI Pharma
by Zacks Equity Research
The Zacks Analyst Blog Highlights: ResMed, Ensign, DaVita, KalVista Pharmaceuticals and MEI Pharma
Zoetis' (ZTS) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
Zoetis (ZTS) beats on both earnings and sales in the fourth quarter of 2019.
New Covid-19 Cases Increase, 5 Defensive Stocks to Buy
by Zacks Equity Research
Here are five defensive stocks that can shield your portfolio as Covid-19 continues to spread, instilling volatility in the stock market.
FibroGen's (FGEN) NDA for Roxadustat Accepted by the FDA
by Zacks Equity Research
The FDA accepts FibroGen's (FGEN) NDA for roxadustat for the treatment of anemia of chronic kidney disease in both non-dialysis-dependent and dialysis-dependent patients.
The Zacks Analyst Blog Highlights: Calavo Growers, Darling Ingredients, The Simply Good Foods Company, KalVista Pharmaceuticals and CareDx
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Calavo Growers, Darling Ingredients, The Simply Good Foods Company, KalVista Pharmaceuticals and CareDx
5 Defensive Stocks to Counter Coronavirus Scare
by Zacks Equity Research
Here are five defensive stocks that can shield your portfolio from China's coronavirus that intimidates to weigh on the stock market.
BioLineRx Concludes Recruitment in Pancreatic Cancer Study
by Zacks Equity Research
BioLineRx (BLRX) closes patient recruitment in the triple combination arm of the phase IIa COMBAT/KEYNOTE-202 study on Motixafortide to treat second-line metastatic pancreatic cancer.
Will KalVista Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in KalVista Pharmaceuticals.
Prospects Appear Bright for Small Drug Industry in 2020
by Kinjel Shah
Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity keep small drugmakers afloat in a competitive market.
Will KalVista Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in KalVista.
KalVista Pharmaceuticals, Inc. (KALV) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in KalVista Pharmaceuticals, Inc. (KALV).
KalVista Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
KalVista Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.
KalVista Pharmaceuticals Enters Oversold Territory
by Zacks Equity Research
KalVista Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
KalVista Group Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
KalVista Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.
KalVista Pharmaceuticals Enters Oversold Territory
by Zacks Equity Research
KalVista Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Moving Average Crossover Alert: KalVista Pharmaceuticals
by Zacks Equity Research
KalVista Pharmaceuticals, Inc. (KALV) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
Rigel Initiates Enrollment in Pivotal Blood Disorder Study
by Zacks Equity Research
Rigel (RIGL) enrolls first patient in a pivotal label expansion study evaluating its approved drug, Tavalisse, in patients with antibody autoimmune hemolytic anemia.
KalVista Pharmaceuticals (KALV) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
KalVista Pharmaceuticals (KALV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Small Drug Stocks Outlook: Near-Term Prospects Encouraging
by Kinjel Shah
Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaboration and M&A activity keep small drugmakers afloat in a competitive market.
Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy
by Kinjel Shah
Smaller drugmakers are having a relatively better 2019 than their larger counterparts. Here are seven stocks to buy.